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LETTERS TO THE EDITORFLOWATCH DEVICE FOR
ADJUSTABLE PULMONARY
ARTERY BANDING
To the Editor:
In a recent article, Di Bardino and
colleagues1 once again are stressing
the importance of having an adjust-
able device for pulmonary artery
banding available in the surgical ar-
mamentarium, particularly for the
management of complex patients,
such as those who require left ventric-
ular retraining.2,3
The advantages of an adjustable de-
vice for pulmonary artery banding
have been proved in other categories of
congenital heart defects, such as func-
tionally univentricular hearts,3 multiple
ventricular septal defects,3 and com-
plete atrioventricular septal defects.4
In all the above categories, includ-
ing congenital heart defects requiring
left ventricular retraining, the favor-
able results obtained by the implanta-
tion of the adjustable FloWatch device
(Leman Medical Technologies SA,
Lausanne, Switzerland) have been re-
ported.2-4
Di Bardino and colleagues,1 recog-
nizing that ‘‘the FloWatch device is
conceptually sound,’’ report that the
device ‘‘is not available in the United
States and is not applicable to all size
patients and all anatomic subtypes.’’
Although it is true that the device
has not received Food and Drug Ad-
ministration approval, it is possible
to obtain limited authorization for im-
plantation in patients in the United
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already done for endless other medical
devices with the CE mark (European
equivalent to Food and Drug Adminis-
tration approval).
With regard to the statement that
the FloWatch device ‘‘is not applica-
ble to all size patients and all anatomic
subtypes,’’ a clarification is required.
The implantation of a FloWatch de-
vice is generally possible even in neo-
nates with a body weight of 2.5 kg or
greater, for all types of congenital
heart defects.2-5
In patients with an anterior aorta,
such as those who require left ventricu-
lar retraining,1,2 there is the risk of
potential coronary artery compression
by the box of the device, by necessity
positioned posteriorly to the ascending
aorta to avoid device compression
at the moment of sternal closure.
Nevertheless, personal and reported
experience proved the feasibility of
this technique even in small neonates.2,3
The same is true for patients with
late referral for left ventricular retrain-
ing, when presentingwith a large sized
pulmonary artery. The FloWatch de-
vice has been successfully implanted
in a patient aged 3 years with a main
pulmonary artery diameter of 3.2 cm.
Finally, for patients with late refer-
ral, potentially requiring a longer
period with the device in situ, the pul-
monary artery can grow and remain
pliable up to 14 months after the de-
vice implantation.5
These clarifications should be use-
ful to expand the use of the FloWatch
device, with several clinical advan-
tages already proved by reports from
different hospitals across Europe.
Antonio F. Corno,
MD, FRCS (Glasgow), FETCS, FACC
Pediatric Cardiac Surgery
Prince Salman Heart Center
King Fahad Medical City
Kingdom of Saudi ArabiaReferences
1. Di Bardino DJ, Kleeman K, Bove EL. A method
of transcutaneously adjustable pulmonary arteryCardiovascular Surgery c April 2013banding for staged left ventricular retraining.
J Thorac Cardiovasc Surg. 2012;144:553-6.
2. Sekarski N, Hurni M, von Segesser LK,
Meijboom EJ, Di Bernardo S. Adaptable pulmo-
nary artery band for late arterial switch procedure
in transposition of the great arteries. Ann Thorac
Surg. 2012;94:1311-6.
3. Corno AF, Ladusans EJ, Pozzi M, Kerr S. FloWatch
versus conventional pulmonary artery banding.
J Thorac Cardiovasc Surg. 2007;134:1413-9.
4. Dhannapuneni RRV, Gladman G, Kerr S,
Venugopal P, Alphonso N, Corno AF. Complete
atrioventricular septal defect: outcome of pulmo-
nary artery banding improved by FloWatch.
J Thorac Cardiovasc Surg. 2011;141:179-82.
5. Corno AF, Prosi M, Fridez P, Zunino P,
Quarteroni A, von Segesser LK. The non-circular
shape of FloWatch-PAB prevents the need for pul-
monary artery reconstruction after banding. Com-
putational fluid dynamics and clinical
correlations. Eur J Cardiothorac Surg. 2006;29:
93-9.
http://dx.doi.org/10.1016/
j.jtcvs.2012.10.053PULSATILE CONTROL OF
ROTARY BLOOD PUMPAND
CARDIAC WORKLOAD
To the Editor:
We were greatly interested in the
recent article by Pirbodaghi and col-
leagues,1 in which they looked into
the influence of rotary blood pump
speed change in synchronization with
electrocardiogram. We are pleased to
know that the rotational speed change
with waveform modulation and phase
change is an additional method to
control cardiac workload. However,
several reports demonstrating similar
results have been already published,
although the authors did not refer to
them. For example, Ando and col-
leagues2 showed the efficacy of the
pulsatile mode with increased rota-
tional speed in the systolic phase in re-
lation to the change in arterial pulse
pressure, maximum derivative of pres-
sure over time, and energy equivalent
pulse pressure. In addition, Umeki and
colleagues3 demonstrated an ability of
the newly developed rotational speed
control algorithm called the ‘‘native
heart load control system’’ to control
left ventricular end-diastolic volume,
which was increased in the co-pulse
mode and decreased in the counter-
pulse mode. Furthermore, an acute
